AVTRAvantor, Inc.
Price
+19%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, nothing alarming, price roughly fair, growth steady, the market undecided.
We are a leading global provider of mission-critical products and services to customers in the biopharma & healthcare, education & government, and advanced technologies & applied materials end markets. Our business model is grounded in supporting our customers from discovery to delivery and Avantor is embedded in virtually every stage of the most important research, scale-up and manufacturing activities in the industries we serve.
In the company’s own words · 10-K filed Feb 11, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Avantor, Inc. (AVTR) reported revenue of $1.69B in Q2 2026 (quarter ended Jun 30, 2026), up 0.5% from the same quarter a year earlier. That came with a gross margin of 32% and net income of $38M (2.3% of revenue). For the full year FY2025, revenue was $6.55B (−3.4% year on year) and net income −$530M. Its largest segment in Q2 2026 was VWR Distribution Services at $1.24B, 73% of the disclosed total, well ahead of Bioscience Medtech Products at 27%. The next results filing is expected around Oct 28, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 21, 2026On September 21, 2026, Avantor, Inc. (the “Company”), announced the appointment of Todd Garner as Executive Vice President and Chief Financial Officer, effective as of September 21, 2026 (the “Commencement Date”)Director or officer change · Form 8-K
- Sep 21, 2026On September 21, 2026, Avantor, Inc. (the “Company”), announced the appointment of Todd Garner as Executive Vice President and Chief Financial Officer, effective as of September 21, 2026 (the “Commencement Date”)Director or officer change · Form 8-K
- Aug 27, 2026On April 23, 2026, Avantor, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original 8-K”) disclosing that Benoit Gourdier, the Company’s Executive Vice President, Bioscience and Medtech Products, would transition to a new role supporting the Company’s segment integration activities for a period of time …Director or officer change · Form 8-K/A
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $1.69BThe company’s own SEC segment disclosure.
- VWR Distribution Services$1.24B73%
- Bioscience Medtech Products$451.8M27%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Medical Instruments & Supplies
Ranks #12 of 20 by RyuScore